RecruitingACTRN12622000664741

Conversion lung transplant patients from Prograf to Advagraf or Envarsus

Pharmacokinetic Study of Conversion Between 2 Formulations of Tacrolimus in Stable Lung Transplant Patients

Sponsor

University Hospital Motol

Enrollment

50 participants

Start Date

Jan 1, 2021

Study Type

Interventional

Conditions

for patient with lung transplantation

Summary

30 days after lung transplantation patients with tacrolimus (Prograf) will be transfered randomisation to once daily tacrolimus (Advagraf, Envarsus) Which product will be better evaluated Advagraf or Envarsus

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 99 Yearss

Inclusion Criteria1

minimum age 18 years, 30 days after lung transplant, need to be prescribed tacrolimus (Advagraf, Envarsus) once daily for 30 days after lung transplant

Exclusion Criteria1

refusal to participate in the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

tacrolimus: dose administered 1 mg once daily the total duration of administration 3 years the mode of administration tablet prolonged release formulation (Advagraf, Envarsus)

Locations(1)

Prague, Czech Republic

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12622000664741